001     282952
005     20260217133533.0
024 7 _ |2 doi
|a 10.1002/mds.70030
024 7 _ |2 pmid
|a pmid:40905240
024 7 _ |2 pmc
|a pmc:PMC12710137
024 7 _ |2 ISSN
|a 0885-3185
024 7 _ |2 ISSN
|a 1531-8257
037 _ _ |a DZNE-2025-01413
041 _ _ |a English
082 _ _ |a 610
100 1 _ |0 0000-0003-2864-0854
|a Al-Azzani, Mohammed
|b 0
245 _ _ |a A Novel α-Synuclein K58N Missense Variant in a Patient with Parkinson's Disease.
260 _ _ |a New York, NY
|b Wiley
|c 2025
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1766068738_31261
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a Parkinson's disease (PD) is a complex multifactorial disorder with a genetic component in about 15% of cases. Multiplications and point mutations in SNCA gene, encoding α-synuclein (aSyn), are linked to rare familial forms of PD.Our goal was to assess the clinical presentation and the biological effects of a novel K58N aSyn mutation identified in a patient with PD.We describe the clinical presentation associated with the novel mutation, together with genetic testing through whole exome sequencing (WES). Furthermore, we conducted extensive biophysical and cellular assays to assess the functional consequences of this novel variant.The patient exhibited typical features of sporadic PD with early onset and a benign disease course. WES showed a novel heterozygous missense variant in SNCA (NM_000345.4, c.174G>C; p.K58N). A positive family history of PD was evident, because both a parent and a grandparent had been diagnosed with PD but were deceased. The patient underwent deep brain stimulation surgery 13 years postdiagnosis, showing stable, long-term improvements in motor symptoms. Biophysical studies demonstrated K58N substitution causes local structural effects, disrupts membrane binding, and enhances aSyn in vitro aggregation. In cellular systems, K58N aSyn produces fewer inclusions per cell and does not form condensates. The variant increases aSyn cytoplasmic distribution and displays aberrant activity-dependent dynamic serine-129 phosphorylation.The clinical presentation associated with the novel K58N aSyn mutation suggests a relatively benign PD course consistent with the phenotypic spectrum of idiopathic PD. Overall, our molecular studies provide novel insight into the biology and pathobiology of aSyn. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |0 G:(DE-HGF)POF4-352
|a 352 - Disease Mechanisms (POF4-352)
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |2 Other
|a Parkinson's disease
650 _ 7 |2 Other
|a genetics
650 _ 7 |2 Other
|a neurodegeneration
650 _ 7 |2 Other
|a protein aggregation
650 _ 7 |2 Other
|a α‐synuclein
650 _ 7 |2 NLM Chemicals
|a alpha-Synuclein
650 _ 7 |2 NLM Chemicals
|a SNCA protein, human
650 _ 2 |2 MeSH
|a Humans
650 _ 2 |2 MeSH
|a alpha-Synuclein: genetics
650 _ 2 |2 MeSH
|a Parkinson Disease: genetics
650 _ 2 |2 MeSH
|a Mutation, Missense: genetics
650 _ 2 |2 MeSH
|a Male
650 _ 2 |2 MeSH
|a Female
650 _ 2 |2 MeSH
|a Middle Aged
650 _ 2 |2 MeSH
|a Exome Sequencing
650 _ 2 |2 MeSH
|a Pedigree
700 1 _ |0 0000-0001-5713-2141
|a Weber, Sandrina
|b 1
700 1 _ |0 0000-0002-9459-3593
|a Ramalingam, Nagendran
|b 2
700 1 _ |a Ramón, Maria
|b 3
700 1 _ |a Shvachiy, Liana
|b 4
700 1 _ |a Mestre, Gonçalo
|b 5
700 1 _ |0 0000-0001-8112-9153
|a Zech, Michael
|b 6
700 1 _ |a Sicking, Kevin
|b 7
700 1 _ |0 P:(DE-2719)2812657
|a de Opakua, Alain Ibáñez
|b 8
|u dzne
700 1 _ |a Jayanthi, Vidyashree
|b 9
700 1 _ |a Amaral, Leslie
|b 10
700 1 _ |a Agarwal, Aishwarya
|b 11
700 1 _ |a Chandran, Aswathy
|b 12
700 1 _ |a Chaves, Susana R
|b 13
700 1 _ |a Winkelmann, Juliane
|b 14
700 1 _ |a Trenkwalder, Claudia
|b 15
700 1 _ |a Schwager, Maike
|b 16
700 1 _ |a Pauli, Silke
|b 17
700 1 _ |a Dettmer, Ulf
|b 18
700 1 _ |a Fernández, Claudio O
|b 19
700 1 _ |a Lautenschläger, Janin
|b 20
700 1 _ |0 P:(DE-2719)2810591
|a Zweckstetter, Markus
|b 21
|u dzne
700 1 _ |a Fernandez-Busnadiego, Ruben
|b 22
700 1 _ |0 P:(DE-2719)9001340
|a Mollenhauer, Brit
|b 23
|u dzne
700 1 _ |0 P:(DE-2719)2814138
|a Outeiro, Tiago Fleming
|b 24
|e Last author
|u dzne
773 _ _ |0 PERI:(DE-600)2041249-6
|a 10.1002/mds.70030
|g Vol. 40, no. 12, p. 2732 - 2745
|n 12
|p 2732 - 2745
|t Movement disorders
|v 40
|x 0885-3185
|y 2025
856 4 _ |u https://pub.dzne.de/record/282952/files/DZNE-2025-01413.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/282952/files/DZNE-2025-01413.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:282952
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |0 I:(DE-588)1065079516
|6 P:(DE-2719)2812657
|a Deutsches Zentrum für Neurodegenerative Erkrankungen
|b 8
|k DZNE
910 1 _ |0 I:(DE-588)1065079516
|6 P:(DE-2719)2810591
|a Deutsches Zentrum für Neurodegenerative Erkrankungen
|b 21
|k DZNE
910 1 _ |0 I:(DE-HGF)0
|6 P:(DE-2719)9001340
|a External Institute
|b 23
|k Extern
910 1 _ |0 I:(DE-588)1065079516
|6 P:(DE-2719)2814138
|a Deutsches Zentrum für Neurodegenerative Erkrankungen
|b 24
|k DZNE
913 1 _ |0 G:(DE-HGF)POF4-352
|1 G:(DE-HGF)POF4-350
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|v Disease Mechanisms
|x 0
914 1 _ |y 2025
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2024-12-16
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
|a Creative Commons Attribution CC BY 4.0
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
|d 2024-12-16
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b MOVEMENT DISORD : 2022
|d 2024-12-16
915 _ _ |0 StatID:(DE-HGF)3001
|2 StatID
|a DEAL Wiley
|d 2024-12-16
|w ger
915 _ _ |0 StatID:(DE-HGF)1030
|2 StatID
|a DBCoverage
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |0 StatID:(DE-HGF)0510
|2 StatID
|a OpenAccess
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
|d 2024-12-16
915 _ _ |0 StatID:(DE-HGF)9905
|2 StatID
|a IF >= 5
|b MOVEMENT DISORD : 2022
|d 2024-12-16
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2024-12-16
915 _ _ |0 StatID:(DE-HGF)1110
|2 StatID
|a DBCoverage
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |0 StatID:(DE-HGF)0420
|2 StatID
|a Nationallizenz
|d 2024-12-16
|w ger
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2024-12-16
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 0
920 1 _ |0 I:(DE-2719)1410001
|k AG Zweckstetter
|l Translational Structural Biology
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a I:(DE-2719)1410001
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21